Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16)

Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16)

In newly diagnosed transplant-ineligible patients with myeloma, daratumumab has improved outcomes when added to the standard-of-care regimens. In a randomized trial, we tested whether similar improvements would be observed when daratumumab was added to the bortezomib, cyclophosphamide, and dexametha...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Simon Gibbs, Sophie Lee, Edwin Lee, Kerry Taylor, Tara Cochrane, Craig T. Wallington‐Beddoe, Fiona Kwok, N Weber, Ian Kerridge, Helen Weston, P. Joy Ho, Michael F. Leahy, Noemi Horvath, Andrew Spencer
Médium: Artigo
Jazyk:angličtina
Vydáno: 2024
On-line přístup:https://doi.org/10.1182/bloodadvances.2023012539
https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2023012539/2225304/bloodadvances.2023012539.pdf
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1182/bloodadvances.2023012539
https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2023012539/2225304/bloodadvances.2023012539.pdf

Podobné jednotky